Molecular cause and functional impact of altered synaptic lipid signaling due to a prg-1 gene SNP.

PubWeight™: 0.84‹?›

🔗 View Article (PMID 26671989)

Published in EMBO Mol Med on December 15, 2015

Authors

Johannes Vogt1, Jenq-Wei Yang2, Arian Mobascher3, Jin Cheng4, Yunbo Li4, Xingfeng Liu4, Jan Baumgart4, Carine Thalman4, Sergei Kirischuk2, Petr Unichenko2, Guilherme Horta4, Konstantin Radyushkin5, Albrecht Stroh4, Sebastian Richers4, Nassim Sahragard4, Ute Distler6, Stefan Tenzer7, Lianyong Qiao4, Klaus Lieb3, Oliver Tüscher3, Harald Binder8, Nerea Ferreiros9, Irmgard Tegeder9, Andrew J Morris10, Sergiu Gropa11, Peter Nürnberg12, Mohammad R Toliat12, Georg Winterer12, Heiko J Luhmann2, Jisen Huai4, Robert Nitsch1

Author Affiliations

1: Institute for Microscopic Anatomy and Neurobiology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany johannes.vogt@unimedizin-mainz.de robert.nitsch@unimedizin-mainz.de.
2: Institute for Physiology and Pathophysiology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
3: Department of Psychiatry and Psychotherapy, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
4: Institute for Microscopic Anatomy and Neurobiology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
5: Focus Program Translational Neuroscience (FTN), University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
6: Focus Program Translational Neuroscience (FTN), University Medical Center, Johannes Gutenberg-University, Mainz, Germany Institute for Immunology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
7: Institute for Immunology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
8: Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
9: Institute of Clinical Pharmacology Goethe-University Hospital, Frankfurt am Main, Germany.
10: Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA.
11: Department of Neurology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany.
12: Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany.

Articles cited by this

A conceptual framework for the neurobiological study of resilience. Behav Brain Sci (2014) 24.16

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23

A tissue-specific atlas of mouse protein phosphorylation and expression. Cell (2010) 8.65

Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature (2011) 8.25

Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol (1991) 6.72

The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev (2005) 4.64

Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol (2006) 4.60

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci (2009) 4.32

Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu Rev Neurosci (2011) 3.16

Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull (2006) 2.92

Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol (2012) 2.83

Impaired PtdIns(4,5)P2 synthesis in nerve terminals produces defects in synaptic vesicle trafficking. Nature (2004) 2.81

Structure of human O-GlcNAc transferase and its complex with a peptide substrate. Nature (2011) 2.24

Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics (2007) 2.23

Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics (2006) 2.09

Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov (2008) 2.05

Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci (2008) 2.04

Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics (2012) 2.03

A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci (2003) 1.95

Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res (2010) 1.92

Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry (1994) 1.90

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80

Chemical approaches to understanding O-GlcNAc glycosylation in the brain. Nat Chem Biol (2008) 1.60

Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59

Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study. Biol Psychiatry (2012) 1.53

Neuroligin-3-deficient mice: model of a monogenic heritable form of autism with an olfactory deficit. Genes Brain Behav (2009) 1.51

Posttranslational regulation of AMPA receptor trafficking and function. Curr Opin Neurobiol (2011) 1.47

Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42

A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther (2010) 1.42

In vivo modulation of O-GlcNAc levels regulates hippocampal synaptic plasticity through interplay with phosphorylation. J Biol Chem (2008) 1.39

Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol (2011) 1.37

Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: post-translational regulation of turnover and transactivation activity. J Biol Chem (2001) 1.33

Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling. Cell (2009) 1.29

Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem (2001) 1.26

Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis. Nat Chem Biol (2012) 1.24

Probing the relative contribution of the first and second responses to sensory gating indices: a meta-analysis. Psychophysiology (2011) 1.15

Genetic and environmental influences on sensory gating of mid-latency auditory evoked responses: a twin study. Schizophr Res (2006) 1.08

Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology (2007) 1.06

Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci U S A (2012) 0.94

Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. Brain Stimul (2011) 0.94

Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review. Neurosci Biobehav Rev (2009) 0.94

Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics (2012) 0.91

Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. J Biol Chem (2011) 0.91

The German multi-centre study on smoking-related behavior-description of a population-based case-control study. Addict Biol (2011) 0.83

Is PRG-1 a new lipid phosphatase? Nat Neurosci (2004) 0.83

P50 sensory gating and smoking in the general population. Addict Biol (2011) 0.81